Европска Унија - Словеначки - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - leflunomid - arthritis, rheumatoid; arthritis, psoriatic - imunosupresivi - leflunomid je indiciran za zdravljenje odraslih bolnikov z:aktivni revmatoidni artritis kot "bolezni spreminjajo antirheumatic drog" (dmard);aktivnim psoriatičnim artritisom. nedavne ali sočasno zdravljenje z hepatotoxic ali haematotoxic dmards (e. metotreksat) lahko poveča tveganje za resne neželene učinke; zato je treba pri teh vidikih koristnosti / tveganja skrbno razmisliti o začetku zdravljenja z leflunomidom. poleg tega je prehod iz leflunomid na drugo dmard brez sledi postopek izpiranja lahko tudi poveča tveganje za resne neželene učinke, še dolgo po tem, ko je preklapljanje.

Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - escitalopram - orodisperzibilna tableta - escitalopram 5 mg / 1 tableta - escitalopram

Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - escitalopram - orodisperzibilna tableta - escitalopram 10 mg / 1 tableta - escitalopram

Словенија - Словеначки - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - escitalopram - orodisperzibilna tableta - escitalopram 20 mg / 1 tableta - escitalopram

Европска Унија - Словеначки - EMA (European Medicines Agency)

dynavax gmbh - površinski antigen hepatitisa b - hepatitis b - cepiva - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Европска Унија - Словеначки - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Европска Унија - Словеначки - EMA (European Medicines Agency)

bial portela & companhia s.a. - opikapon - parkinsonova bolezen - anti-parkinsonska zdravila - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Европска Унија - Словеначки - EMA (European Medicines Agency)

viatris healthcare limited - imikvimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiotiki in kemoterapevtiki za dermatološko uporabo - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

Европска Унија - Словеначки - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - granisetron - vomiting; cancer - antiemetics in antinauseants, serotonina (5ht3) antagonisti - preprečevanje navzee in bruhanja pri bolnikih, ki prejemajo zmerno ali visoko emetogeno kemoterapijo, z ali brez cisplatina, do pet zaporednih dni. sancuso se lahko uporablja pri bolnikih, ki prejemajo svojo prvo kemoterapijo režim, ali pri bolnikih, ki so že prejeli kemoterapijo.

Европска Унија - Словеначки - EMA (European Medicines Agency)

janssen-cilag international nv - fentanil hidroklorid - bolečina, postoperativna - analgetiki - zdravljenje akutne zmerne do hude pooperativne bolečine za uporabo v bolnišničnem okolju.